Otezla 30 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FM50Q
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,196
Award facts
- Contract value 100% obligated
- $29,196.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, awarded January 30, 2026, provides OTEZLA 30 mg tablets (60-count) to the Defense Logistics Agency (DLA) through AmerisourceBergen Drug Corp, the prime contractor. Valued at $29,196.10 with a firm fixed-price structure and no set-aside designation, the order is set for completion by February 2, 2026, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award falls under the parent company Cencora, Inc.'s significant Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2031, which serves as a comprehensive pharmaceutical support vehicle for military healthcare programs globally.
The DLA, a defense agency within the Department of Defense, procures pharmaceuticals and medical supplies to support military treatment facilities and veteran healthcare systems. OTEZLA (apremilast) is an oral immunomodulatory agent used for treating inflammatory conditions such as psoriasis and psoriatic arthritis. AmerisourceBergen, as a major pharmaceutical distributor and healthcare solutions provider, maintains a robust portfolio of federal contracts demonstrating its capability to meet complex medical supply requirements through competitive procurement channels. The company's extensive experience delivering diverse pharmaceutical products across multiple therapeutic domains positions it as a critical vendor within the federal medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FM50Q?
SPE2DR26FM50Q was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FM50Q worth?
The government has obligated $29,196 on SPE2DR26FM50Q.
Is contract SPE2DR26FM50Q an order under another contract?
Yes. SPE2DR26FM50Q is a delivery order under SPE2DR25D2007, an indefinite delivery contract.
Was contract SPE2DR26FM50Q competed?
The extent of competition for SPE2DR26FM50Q was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award